TET2 and leukemia: Furthermore, compared to the DMSO group, the proliferation of TET2-mutated leukemia cells was significantly reduced in the BM of recipient mice treated with H-151, and no inhibitory effect was observed in the recipients of leukemia cells harboring wildtype TET2 (Fig. 5C and Supplementary Fig. 8D).